Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?

Conclusions
An extended dosing interval for rituximab for patients with stable MS during the COVID-19 pandemic may be associated with a low risk of disease activity.

Source: Neurology Neuroimmunology and Neuroinflammation - June 24, 2020 Category: Neurology Authors: Maarouf, A., Rico, A., Boutiere, C., Perriguey, M., Demortiere, S., Pelletier, J., Audoin, B., Under the aegis of OFSEP Tags: COVID-19, Multiple sclerosis, Cohort studies Article Source Type: research